ライフサイエンスコーパス: Plasmodium vivax

1 ver, RDTs are known to perform less well for Plasmodium vivax.

2 known entry point for the malarial parasite Plasmodium vivax.

3 which mediates invasion of reticulocytes by Plasmodium vivax.

4 Iraq with life-threatening infection due to Plasmodium vivax.

5 ers protection against malarial infection by Plasmodium vivax.

6 not found in individuals infected only with Plasmodium vivax.

7 est children and for the non-lethal parasite Plasmodium vivax.

8 Anopheles gambiae, Plasmodium falciparum and Plasmodium vivax.

9 of studies conducted in humans infected with Plasmodium vivax.

10 PMV isolated from Plasmodium falciparum and Plasmodium vivax.

11 n and factors affecting rosette formation in Plasmodium vivax.

12 gle and mixed infection of P. falciparum and Plasmodium vivax.

13 the life cycle of Plasmodium falciparum and Plasmodium vivax.

14 Also present were Plasmodium vivax (14.3%), Plasmodium falciparum (10.5%)

15 stem measures presence of antibodies against Plasmodium vivax, a causing agent for malaria.

16 enetic diversity and population structure of Plasmodium vivax, a debilitating and highly prevalent ma

17 Plasmodium vivax, a major agent of malaria in both tempe

18 Plasmodium vivax accounts for 65% of all cases of malari

19 ck transmission of Plasmodium falciparum and Plasmodium vivax across distantly related anopheline spe

20 We now report crystal structures of Plasmodium vivax ADA in complex with adenosine, guanosin

21 y and efficacy of DB289 for the treatment of Plasmodium vivax and acute, uncomplicated P. falciparum

22 ions of the human genome, and the genomes of Plasmodium vivax and Arabidopsis thaliana show that Evig

23 ic affinity of the malaria causing parasites Plasmodium vivax and falciparum in historic southern Eur

24 examine the association between relapses of Plasmodium vivax and febrile infectious diseases.

25 s, has been identified in the human parasite Plasmodium vivax and homologues (yir) of this family exi

26 nomic databases of Plasmodium falciparum and Plasmodium vivax and investigated as candidate antigens

27 rapid diagnostic tests (RDTs) for diagnosing Plasmodium vivax and nonfalciparum malaria in endemic ar

28 from P. knowlesi, Plasmodium falciparum, and Plasmodium vivax and outcomes following introduction of

29 Plasmodium vivax and P. cynomolgi produce numerous caveo

30 etectable hypnozoite reservoir for relapsing Plasmodium vivax and P. ovale malarias presents a major

31 Cambodia, in which both Plasmodium vivax and Plasmodium falciparum are endemic,

32 ents containing the VWA and TSR domains from Plasmodium vivax and Plasmodium falciparum in different

33 iMAL (Flow Inc., Portland, Oreg.), to detect Plasmodium vivax and Plasmodium falciparum malaria durin

34 biochemical properties of PMT orthologs from Plasmodium vivax and Plasmodium knowlesi and show that b

35 pt that hypnozoites give rise to relapses in Plasmodium vivax and Plasmodium ovale malaria has become

36 tivation of quiescent hepatic hypnozoites of Plasmodium vivax and Plasmodium ovale, hinder global eff

37 Studies of the interaction between Plasmodium vivax and the Duffy antigen provide the clear

38 Plasmodium vivax and the related simian malarial parasit

39 is caused by a distinct Plasmodium species, Plasmodium vivax, and it has become increasingly apparen

40 uch as the Duffy blood group, a receptor for Plasmodium vivax, and the Gerbich-negative modification

41 one separately for Plasmodium falciparum and Plasmodium vivax, and the limitations of the approach we

42 distributions for Plasmodium falciparum and Plasmodium vivax, and the proportions of undetected infe

43 enic clearance of the rheologically impaired Plasmodium vivax- and Plasmodium falciparum-infected RBC

44 e MBC, and their levels correlated with both Plasmodium vivax- and Plasmodium falciparum-specific pla

45 The parasites Plasmodium falciparum and Plasmodium vivax are responsible for the majority of hum

46 asmodium falciparum (asexual and sexual) and Plasmodium vivax (asexual) as well as oral in vivo effic

47 es show the importance of the bone marrow in Plasmodium vivax biology by proving the preferential inf

48 hrocyte receptor is critical for maintaining Plasmodium vivax blood-stage infections, making DBP an a

49 binding protein (DBP) is a vital ligand for Plasmodium vivax blood-stage merozoite invasion, making

50 Plasmodium vivax can be associated with placental infect

51 enign disease, it is now becoming clear that Plasmodium vivax can cause significant morbidity.

52 tively, with correct identification of all 5 Plasmodium vivax cases.

53 Plasmodium vivax causes 25-40% of malaria cases worldwid

54 Plasmodium vivax causes the most geographically widespre

55 te increasing evidence of the development of Plasmodium vivax chloroquine (CQ) resistance, there have

56 apled" lipid vesicles carrying a recombinant Plasmodium vivax circumsporozoite antigen, VMP001, both

57 In areas where Plasmodium falciparum and Plasmodium vivax coexist and treatments for the 2 specie

58 piens/Mus musculus and Plasmodium falciparum/Plasmodium vivax comparisons).

59 inical illness with Plasmodium falciparum or Plasmodium vivax compromises the function of dendritic c

60 Plasmodium vivax contains the largest number of such ant

61 The recent research efforts to establish a Plasmodium vivax continuous, long-term blood-stage cultu

62 m and Plasmodium berghei sporozoites by anti-Plasmodium vivax CSP serum samples.

63 ction from clinical vivax malaria or reduced Plasmodium vivax density, including Southeast Asian oval

64 FN-gamma-mediated restriction of liver-stage Plasmodium vivax depends only on the downstream autophag

65 It is likely that Plasmodium vivax diverged approximately 2 million years

66 Plasmodium vivax Duffy binding protein (DBP) is a conser

67 Plasmodium vivax Duffy binding protein (DBP) is a merozo

68 Antibodies to the cysteine-rich domain II of Plasmodium vivax Duffy binding protein (PvDBP) can inhib

69 Plasmodium vivax Duffy Binding Protein (PvDBP) is the mo

70 against a farnesyl diphosphate synthase from Plasmodium vivax, finding a poor correlation between enz

71 for which long term culture is possible, and Plasmodium vivax, for which no long-term culture is feas

72 Plasmodium vivax forms long-lasting hypnozoites in the l

73 ssion of vivax malaria requires knowledge of Plasmodium vivax gametocyte dynamics.

74 rstanding of the structure and regulation of Plasmodium vivax genes is limited by our inability to gr

75 Here, an update on the Plasmodium vivax genome sequencing project is presented,

76 d and characterized a novel parasite ligand, Plasmodium vivax GPI-anchored micronemal antigen (PvGAMA

77 The human malaria parasite Plasmodium vivax has been shown to regulate the transcri

78 Controversially, it is also thought that Plasmodium vivax has driven the recent selection of G6PD

79 dence and range of endemic malaria caused by Plasmodium vivax has expanded during the past 30 years.

80 Plasmodium vivax has received less attention and study t

81 The evolutionary history of Plasmodium vivax has recently been addressed in terms of

82 th Ki values as low as 0.08 and 0.01 muM for Plasmodium vivax HGPRT (PvHGPRT).

83 me diversity of the important human pathogen Plasmodium vivax, however, remains essentially unknown.

84 ne is the only licensed drug for eradicating Plasmodium vivax hypnozoites and, therefore, preventing

85 er stages for both Plasmodium falciparum and Plasmodium vivax in a microscale human liver platform co

86 A high prevalence of chloroquine-resistant Plasmodium vivax in Indonesia has shifted first-line tre

87 t primaquine is the first-line treatment for Plasmodium vivax in malarious areas, but artemether-lume

88 Malaria is increasingly imported, caused by Plasmodium vivax in settings outside sub-Saharan Africa,

89 Evidence of the presence of Plasmodium vivax in the placenta is scarce and inconclus

90 idence that challenges the current view that Plasmodium vivax-infected erythrocyte (Pv-iE) are unable

91 fected patients were lower than those in the Plasmodium vivax-infected patients, which, in turn, were

92 effectiveness of previous regimens to treat Plasmodium vivax infection have been hampered by complia

93 Prevention of relapse of Plasmodium vivax infection is a key treatment goal in ma

94 Severe disease attributable to Plasmodium vivax infection is already well described wor

95 mplicated P falciparum or mixed P falciparum/Plasmodium vivax infection of between 1000 and 200,000 p

96 es and endothelial cells and is required for Plasmodium vivax infection of erythrocytes.

97 receptor for chemokines that is required for Plasmodium vivax infection of erythroid cells.

98 espread distribution and relapsing nature of Plasmodium vivax infection present major challenges for

99 halassemia may facilitate so-called "benign" Plasmodium vivax infection to act later in life as a "na

100 xed infections, 3.73 (95% CI, 3.51-3.97) for Plasmodium vivax infection, and 2.16 (95% CI, 1.78-2.63)

101 7 (2%) with Plasmodium falciparum infection, Plasmodium vivax infection, Plasmodium malariae/Plasmodi

102 group-believed to confer resistance against Plasmodium vivax infection-was recently introduced to Pa

103 rred by the Duffy-negative phenotype against Plasmodium vivax infection.

104 Plasmodium vivax infections often recur due to relapse o

105 Plasmodium vivax infections remain a major source of mal

106 Plasmodium vivax invasion into human reticulocytes is a

107 Plasmodium vivax invasion of human erythrocytes requires

108 Plasmodium vivax is a major cause of malaria morbidity w

109 Plasmodium vivax is a major public health burden, respon

110 Plasmodium vivax is a serious health concern in many reg

111 Erythrocyte invasion by Plasmodium vivax is completely dependent on binding to t

112 Plasmodium vivax is considered to be absent from Central

113 However, the proportion of cases due to Plasmodium vivax is increasing, accounting for up to 90-

114 Chloroquine (CQ)-resistant Plasmodium vivax is increasingly reported throughout sou

115 Plasmodium vivax is one of four Plasmodium species that

116 The human malaria parasite Plasmodium vivax is responsible for 25-40% of the approx

117 Plasmodium vivax is the leading cause of human malaria i

118 Plasmodium vivax is the major cause of malaria outside s

119 Plasmodium vivax is the most prevalent parasite species

120 Plasmodium vivax is the most widespread species of Plasm

121 Plasmodium vivax is the world's most widely distributed

122 r reinfection with Plasmodium falciparum and Plasmodium vivax is unknown.

123 morphic microsatellite markers to analyze 74 Plasmodium vivax isolates, which we collected in cross-s

124 d host invasion by Plasmodium falciparum and Plasmodium vivax--major causative organisms of human mal

125 expression in a rhesus monkey model of human Plasmodium vivax malaria (P. cynomolgi in Macaca mulatta

126 e used for the radical curative treatment of Plasmodium vivax malaria and can cause haemolysis in G6P

127 on spatio-temporal epidemiological cases of Plasmodium vivax malaria and land-use irrigation from re

128 ylactic regimens fail to prevent relapses of Plasmodium vivax malaria and review available options.

129 DARC acts as a receptor for Plasmodium vivax malaria and the DARC-null genotype has

130 nts to development of vaccines and drugs for Plasmodium vivax malaria are the inability to culture th

131 The radial distribution of Plasmodium vivax malaria burden has evoked enormous conc

132 spective infant cohort, 21 infants developed Plasmodium vivax malaria during their first year.

133 Chloroquine is the first-line treatment for Plasmodium vivax malaria in most endemic countries, but

134 Plasmodium vivax malaria increased the odds of stillbirt

135 Plasmodium vivax malaria is characterized by periodic re

136 Pathogenesis of severe Plasmodium vivax malaria is poorly understood.

137 Chloroquine (CQ)-resistant Plasmodium vivax malaria was first reported 12 years ago

138 Radical cure of Plasmodium vivax malaria with 8-aminoquinolines (primaqu

139 A successful vaccine against Plasmodium vivax malaria would significantly improve the

140 tes might not be the only cause of recurrent Plasmodium vivax malaria.

141 taemia, or pregnancy-associated malaria, and Plasmodium vivax malaria.

142 and the spleen has been reported in cases of Plasmodium vivax malaria.

143 es in patients with Plasmodium falciparum or Plasmodium vivax malaria.

144 pLDH from Plasmodium vivax, malariae, and ovale exhibit 90-92% ide

145 The Plasmodium vivax merozoite Duffy binding protein (DBP) c

146 The interaction between the Plasmodium vivax merozoite Duffy binding protein region

147 Plasmodium vivax merozoite invasion is totally dependent

148 206) who acquire high antibody levels to two Plasmodium vivax merozoite proteins, Duffy binding prote

149 The Plasmodium vivax merozoite surface protein 1 (MSP-1) 42-

150 mbinant protein containing the C terminus of Plasmodium vivax merozoite surface protein 1 and two T-h

151 Using a newly developed Plasmodium vivax merozoite surface protein 1 gene (Pvmsp

152 Two recombinant protein subunits of the Plasmodium vivax merozoite surface protein 1 have been s

153 heteroduplex tracking assay used to genotype Plasmodium vivax merozoite surface protein 1 was adapted

154 Plasmodium vivax merozoites only invade reticulocytes, a

155 usly reported a method for the production of Plasmodium vivax MSP-1(42) (PvMSP-1(42)) as a soluble pr

156 port the successful discovery of a series of Plasmodium vivax NMT inhibitors by high-throughput scree

157 s allele has been the target of selection by Plasmodium vivax or some other infectious agent.

158 b-Saharan Africa has been used to argue that Plasmodium vivax originated on that continent.

159 Plasmodium vivax (P. vivax) is one of the most important

160 ence and micro-geographical heterogeneity of Plasmodium vivax parasitaemia in communities of the Peru

161 rasite development of both P. falciparum and Plasmodium vivax parasites in five different species of

162 Two new studies confirm that Plasmodium vivax populations are more diverse than Plasm

163 e is known about allelic variants of dhfr in Plasmodium vivax populations.

164 The most widespread Plasmodium species, Plasmodium vivax, poses a significant public health thre

165 Plasmodium vivax preferentially invades reticulocytes, w

166 ctive against the dormant relapsing forms of Plasmodium vivax, primaquine is the sole effective treat

167 To evaluate whether the recently cloned Plasmodium vivax proteins Pvs25 and Pvs28 are candidates

168 bitors of the Plasmodium falciparum (Pf) and Plasmodium vivax (Pv) 6-oxopurine phosphoribosyltransfer

169 Plasmodium vivax (Pv) is a major cause of human malaria

170 inhibitors of Plasmodium falciparum (Pf) and Plasmodium vivax (Pv) NMT.

171 inhibitors of Plasmodium falciparum (Pf) and Plasmodium vivax (Pv) SHMT with a pyrazolopyran core str

172 ial parasites Plasmodium falciparum (Pf) and Plasmodium vivax (Pv).

173 Here, the crystal structure of ADA from Plasmodium vivax (PvADA) in a complex with MT-coformycin

174 ed with the sexual-stage-specific antigen of Plasmodium vivax, Pvs25, as a negative control, and the

175 Plasmodium vivax relapse infections occur following acti

176 malaria in humans, Plasmodium falciparum and Plasmodium vivax, rely on two distinct host cell surface

177 The population structure of Plasmodium vivax remains elusive.

178 Plasmodium vivax, requires the Duffy blood group antigen

179 search: 2002 and Beyond, devoted entirely to Plasmodium vivax research.

180 isks of elimination are presented, including Plasmodium vivax, resistance in the parasite and mosquit

181 laria cases are caused by its distant cousin Plasmodium vivax, resulting in a daunting morbidity and

182 been identified by comparative analyses with Plasmodium vivax reticulocyte binding protein 2 (PvRBP-2

183 e binding protein 1 (PfNBP1), an ortholog of Plasmodium vivax reticulocyte binding protein-1.

184 Crucial gaps in our understanding of Plasmodium vivax reticulocyte invasion and protective im

185 onal antibody directed against a proprietary Plasmodium vivax-specific antigen, in addition to the an

186 Plasmodium vivax sporozoites consist of tachysporozoites

187 Plasmodium vivax synthesizes the largest number of 36 tr

188 parasites such as Plasmodium falciparum and Plasmodium vivax, the causative agents of malaria.

189 mprising HIV-1, the malaria-causing parasite Plasmodium vivax, the fungus Aspergillus niger, and the

190 The difficulty in controlling Plasmodium vivax, the most common cause of human malaria

191 Plasmodium vivax, the most widely distributed human mala

192 it has a close phylogenetic relationship to Plasmodium vivax, the second most important species of h

193 he development of vaccine candidates against Plasmodium vivax-the most geographically widespread huma

194 ocked transmission of Plasmodium berghei and Plasmodium vivax to Anopheles gambiae and Anopheles diru

195 The ability of the malaria parasite Plasmodium vivax to invade erythrocytes is dependent on

196 The Plasmodium vivax TRAg (PvTRAg) family includes 36 member

197 spatial limits of Plasmodium falciparum and Plasmodium vivax transmission on a global scale.

198 Recently, we have characterized a Plasmodium vivax tryptophan-rich antigen PvTRAg38, which

199 Plasmodium vivax uses a single member of the Duffy bindi

200 we describe the development of a multistage Plasmodium vivax vaccine which simultaneously expresses

201 Later evolution of long latency in Plasmodium vivax was a necessary adaptation as early hom

202 Dengue and malaria, predominantly Plasmodium vivax, were the most frequently identified sp

203 f coendemicity for Plasmodium falciparum and Plasmodium vivax where mefloquine is used to treat P. fa

204 In contrast to Plasmodium vivax, which has disappeared from West Africa

205 We present evidence from one such species, Plasmodium vivax, which has experienced sustained select

206 t widely distributed human malaria parasite, Plasmodium vivax, will be a major step towards malaria e

207 nt years, there has been renewed interest in Plasmodium vivax, with CHMI models developed by groups i

208 Plasmodium vivax, with its dormant liver stage, will be